Ganymed Pharmaceuticals AG;TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GmbH
发明人:
Sahin, Ugur,Tureci, Ozlem
申请号：
AU2014234684
公开号：
AU2014234684A1
申请日:
2014.03.17
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN 18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
